신장이식 환자에서 HCMV 항원혈증 검사의 임상적 유용성
Clinical Usefulness of Human Cytomegalovirus Antigenemia Assay after Kidney Transplantation
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background : This study was performed to determine the cut-off value and the predictability of symptomatic human cytomegalovirus (HCMV) infection according to the peak value of HCMV antigenemia assay in kidney transplant recipients. Materials and Methods : We reviewed the results of HCMV antigenemia assay (Chemicon, CA, USA) in patients who received kidney transplantation at our institution from May 2003 through May 2008, and investigated the existence and the type of HCMV infection by the medical record review. Patients who underwent the test only once during the episode or those who received ganciclovir for more than 48hrs before the test were excluded. The receiver-operator characteristic curve was drawn and the point showing maximum likelihood ratio (LR) was chosen as the cut-off value of symptomatic HCMV infection. Results : A total of 689 episodes were screened and 134 episodes were enrolled. Thirty-three (24.6 %) episodes were symptomatic HCMV infection, 23 (17.2%) episodes were associated with HCMV syndrome, and 10 (7.5%) episodes were tissue-invasive diseases. The maximum LR was 7.5 (95% confidence interval, 4.014.2) and the cut-off value was 29.5 cells/200,000 WBC. The sensitivity, specificity, positive predictive value, and negative predictive value were 66.7%, 91.1%, 71.0%, and 89.3%, respectively. Conclusions : The cut-off value of symptomatic HCMV infection by the peak value of HCMV antigenemia assay in our study was similar with previous results, although the sensitivity was relatively low.
Abstract
Background : This study was performed to determine the cut-off value and the predictability of symptomatic human cytomegalovirus (HCMV) infection according to the peak value of HCMV antigenemia assay in kidney transplant recipients. Materials and Methods : We reviewed the results of HCMV antigenemia assay (Chemicon, CA, USA) in patients who received kidney transplantation at our institution from May 2003 through May 2008, and investigated the existence and the type of HCMV infection by the medical record review. Patients who underwent the test only once during the episode or those who received ganciclovir for more than 48hrs before the test were excluded. The receiver-operator characteristic curve was drawn and the point showing maximum likelihood ratio (LR) was chosen as the cut-off value of symptomatic HCMV infection. Results : A total of 689 episodes were screened and 134 episodes were enrolled. Thirty-three (24.6 %) episodes were symptomatic HCMV infection, 23 (17.2%) episodes were associated with HCMV syndrome, and 10 (7.5%) episodes were tissue-invasive diseases. The maximum LR was 7.5 (95% confidence interval, 4.014.2) and the cut-off value was 29.5 cells/200,000 WBC. The sensitivity, specificity, positive predictive value, and negative predictive value were 66.7%, 91.1%, 71.0%, and 89.3%, respectively. Conclusions : The cut-off value of symptomatic HCMV infection by the peak value of HCMV antigenemia assay in our study was similar with previous results, although the sensitivity was relatively low.
참고문헌 (18)
- Fishman JA, "Infection in solid-organ transplant recipients", N Engl J Med, 357, pp.2601~2614 (2007)
- Holdinka RL, "Human cytomegalovirus in Manual of clinical microbiology", pp.1549~ (2007), ASM Press
- Gerna G, "Standardization of the human cytomegalovirus antigenemia assay by means of in vitro-generated pp65- positive peripheral blood polymorphonuclear leukocytes", J Clin Microbiol, 36, pp.3585~3589 (1998)
- Mhiri L, "Comparison of pp65 antigenemia, quantitative PCR and DNA hybrid capture for detection of cytomegalovirus in transplant recipients and AIDS patients", J Virol Methods, 143, pp.23~28 (2007)
- Machado CM, "CMV pneumonia in allogeneic BMT recipients undergoing early treatment of pre-emptive ganciclovir therapy", Bone Marrow Transplant, 26, pp.413~417 (2000)
- 기현균, "간이식 환자에서 CMV 항원혈증 검사의 임상적 유용성에 대한 고찰", Infection and Chemotherapy, 37(4), pp.199~207 (2005), 대한감염학회
- Niubò J, "Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients", Diagn Microbiol Infect Dis, 24, pp.19~24 (1996)
- Yang CW, "Clinical course of cytomegalovirus (CMV) viremia with and without ganciclovir treatment in CMV-seropositive kidney transplant recipients", Am J Nephrol, 18, pp.373~378 (1998)
- Kim CK, "Clinical usefulness of human cytomegalovirus antigenemia assay after kidney transplantation", Transplantation, 75, pp.2151~2155 (2003)
- Sagedal S, "A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients", Transplantation, 70, pp.1166~1174 (2000)
- Piiparinen H, "Comparison of plasma polymerase chain reaction and pp65-antigenemia assay in the quantification of cytomegalovirus in liver and kidney transplant patients", J Clin Virol, 22, pp.111~116 (2001)
- Humar A, "AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation", Am J Transplant, 6, pp.262~274 (2006)
- Kahng KW, "Study of cytomegalovirus infection in renal transplant recipients who had IgG CMV antibody in the pretransplantation period", Korean J Nephrol, 16, pp.123~135 (1997)
- Ki HK, "Cytomegalovirus infections after renal transplantation", Korean J Infect Dis, 31, pp.341~345 (1999)
- van den Berg AP, "Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation-a report of 130 consecutive patients", Transplantation, 48, pp.991~995 (1989)
- Meyer-Koenig U, "Cytomegalovirus infection in organ-transplant recipients: diagnostic value of pp65 antigen test, qualitative polymerase chain reaction (PCR) and quantitative Taqman PCR", Transplantation, 77, pp.1692~1698 (2004)
- Degré M, "Detection of human cytomegalovirus (HCMV) pp67- mRNA and pp65 antigenemia in relation to development of clinical HCMV disease in renal transplant recipients", Clin Microbiol Infect, 7, pp.254~260 (2001)
- Brennan DC, "Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients", Transplantation, 64, pp.1843~1846 (1997)